Chemotherapy plus durvalumab combinations show promise in advanced biliary tract cancer
Gemcitabine and cisplatin plus durvalumab, with or without tremelimumab, produced favorable outcomes as first-line treatment for advanced biliary tract cancer, according to research.“Immune checkpoint inhibitors have been assessed in biliary tract cancer and have shown clinical activity,” Do-Youn Oh, MD, of the division of medical oncology at Seoul National University Hospital, and colleagues wrote in The Lancet. “Furthermore, chemotherapeutic agents, including gemcitabine and cisplatin, have been shown to induce immunomodulatory effects. Study findings from 2019 in patientsRead More
